Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Kohei ShitaraRui-Hua XuJaffer A AjaniDiarmuid MoranAbraham GuerreroRan LiJanet PaveseMaria MatsangouPranob BhattacharyaYoko UenoXuewei WangManish A ShahPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)
CLDN18.2 was a highly prevalent biomarker in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma. CLDN18.2 positivity remained relatively stable over time in many patients. Biomarker testing for CLDN18.2 should be considered in standard clinical practice in these patients.
Keyphrases
- locally advanced
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical practice
- rectal cancer
- prognostic factors
- small cell lung cancer
- peritoneal dialysis
- neoadjuvant chemotherapy
- patient reported outcomes
- risk factors
- phase ii study
- liver metastases
- open label
- placebo controlled